DAFTAR PUSTAKA

1.

WHO. International travel and health. World Health Organization, Geneva

2003.

2.

World Tourism Organization. Tourism highlights. Madrid; World Tourism

Organization, 2000.

3.

Handszuh H. Tourism trends and patterns. European Conference on Travel

Medicine.
Venice,
Cini
Foundation,
25-27
March
1998.
www.ectm5.org/1998.pdf

4.

Zuckerman JN. 2002. Recent developments: Travel medicine. BMJ ;325: 260-4.

5.

Anonim. Travel Medicine: Helping Patients Prepare for Trips Abroad.

http://www.aafp.org/afp/980800ap/dick.html

6.

World Health Organization. International Travel and Health. Geneva: World

Health Organization, 2005.

7.

Hugo, Graeme. 2011. Mobilitas Penduduk Dari Di Dalam Dan Di Luar Negeri:
Implikasi Untuk Penyebaran HIV/AIDS. UNDP South East Asia HIV And
Development Office, UNAIDS, Indonesia.

8.

Guest, P., 2000. Population Mobility in Asia and the Implictions for HIV/AIDS,
pp. 76-86 in UNDP South East Asia HIV and Development Project, Population
Mobility in Asia: Implications for HIV/AIDS Action Programmes, UNDP, South
East Asia HIV and Development Project, Bangkok.

9.

White, R., Kintu, P.B., Orroth, K.K., Korenromp, E.L., Mwita, W., Gray, R.H.,
Kamali, A.,Sewankambo, N.K., Wawer, M.J., Whitworth, J.A.G., Grosskurth,
H., Hayes, R.J.and Zaba, B., 2001. Impact of Mobility on HIV Spread in Rural
East Africa. Paper presented at IUSSP Conference, Session S28, Mobility and
HIV in East Africa, Brazil, August.

10.

Anonim. 2006. Gawat, Kasus HIV/AIDS di Indonesia Meningkat.

http://www.jawapos.com/
index.php?act=detail_radar&id=116329&c=85
(Akses: 31 Desember 2011).

11.

UNAIDS/WHO. 2010. Report on The Global AIDS Epidemic. Jenewa.

12.

Powderly W. Limitations of current HIV therapies: opportunities for

improvement. J Acquir Immune Defic Syndr 2003;33 (suppl 1):7-12.

13.

De Clercq E. New anti-HIV agents and targets. Med Res Rev 2002;22:531-65.

14.

Handayani,Sarwo. 2001.
Kedokteran; 130: 5-8.

15.

Evelyn Phangkawira, Kiki MK Samsi. 2009. Vaksin HIV, Harapan atau

Khayalan?.Cermin Dunia Kedokteran. 170: vol.36: 4.

Pengembangan

Vaksin

HIV.

Cermin

Dunia

16.

Anonim. 2009. Vaksin HIV Terus Dikembangkan.

cyberMEDIA.com. htm. (Akses: 31 Desember 2011).

http://Kliping

17.

Steven G Deeks & Joseph M McCune. 2010. Can HIV be cured with stem cell
therapy?. Nature Biotechnology: Vol: 28; 802-807.

18.

Gero Htter, Thomas Schneiderk, Eckhard Thiel. Transplantation of selected or

transgenic blood stem cells a future treatment for HIV/AIDS?. Journal of the
International AIDS Society; 2009, 12:10. 1-5.

19.

Letvin N, Walker B. Immunopathogenesis and immunotherapy in AIDS virus

infections. Nat Med 2003;9:861-6.

20.

Michael, N. L., Louie, L. G., and Sheppard, H. W. (1997). CCR5-delta 32 gene

deletion in HIV-1 infected patients. Lancet. 350: 741742.

21.

Htter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, SchneiderT,

Hofmann J, Kucherer C, Blau O, Blau IW, Hofmann WK,Thiel E: Long-term
control of HIV by CCR5 Delta32/Delta32stem-cell transplantation. N Engl J
Med 2009, 360(7):692-698.

22.

David T. Scadden, Hongmei Shen, Tao Cheng. Hematopoietic Stem Cells in

HIV Disease. J Natl Cancer Inst Monogr 2000; 28:249.

23.

Bank A. Hematopoietic Stem Cell Gene Therapy: Selecting Only The Best. J
Clin Invest 2003;112:1478-80.

24.

Johan van Griensven, Erik De Clercq and Zeger Debyser. Hematopoietic Stem
Cell-based Gene Therapy Against HIV Infection: Promises and Caveats. AIDS
Review 2005; 7: 44-55.

25.

Kristina Allers,Gero Hutter,Jorg Hofmann, Christoph Loddenkemper,Kathrin

Rieger,Eckhard Thiel,Thomas Schneider. Evidence For The Cure of HIV
Infection by CCR532/32 Stem Cell Transplantation. Blood 2011; 117: 10;
2791-2799.

26.

Cartier N. Hematopoietic Stem Cell Gene Therapy With A Lentiviral Vector In

X-Linked Adrenoleukodystrophy. Science. 2009; 326:818823. [PubMed:
19892975].

27.

Cavazzana-Calvo, M., S. Hacein-Bey,. Gene Therapy Of Human Severe

Combined Immunodeficiency (SCID)-X1 Disease. Science 2000; 288(5466):
669-672.

28.

Scott Ledger, Borislav Savkovic, Michelle Millington, Helen Impey, Maureen

Boyd, John M. Murray and Geoff Symonds. Cell-Delivered Gene Therapy for
HIV. Recent Translational Research in HIV/AIDS; 2011. Chapter 20: 405-430.

29.

Schambach A. Towards hematopoietic stem cell-mediated protection against

infection with human immunodeficiency virus. Gene Ther 2006;13:103747.
[PubMed: 16541120]

30.

Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. Nat Biotechnol.
2007; 25:14441454. [PubMed: 18066041].

31.

Hannon, G. J. and J. J. Rossi. Unlocking the potential of the human genome

with RNA interference. Nature 2004; 431(7006): 371-378.

32.

Downward, J. 2004. RNA interference. British Medical Journal 328:1245-1248.

33.

Leonard, J. N. and D. V. Schaffer. Antiviral RNAi therapy: emerging

approaches for hitting a moving target. Gene Ther 2006; 13(6): 532-540.

34.

Kootstra, N. A. and I. M. Verma. Gene therapy with viral vectors.Annu Rev

Pharmacol Toxicol 2003; 43: 413-439.

35.

DiGiusto, D.L., Krishnan, A., Li, L., Li, H., Li, S., Rao, A., Mi, S., Yam, P.,
Stinson, S., Kalos, M.,Alvarnas, J., Lacey, S.F., Yee, J.K., Li, M., Couture, L.,
Hsu, D., Forman, S.J., Rossi, J.J., Zaia, J.A. RNA-based gene therapy for HIV
with lentiviral vector-modified CD34(+) cells in patients undergoing
transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2010. 2 (36),
36ra43.

36.

McIntyre, G. J. and G. C. Fanning. Design and cloning strategies for

constructing shRNA expression vectors. BMC Biotechnol 2006; 6: 1.

37.

Scott G. Kitchen,Saki Shimizu, Dong Sung An. Stem cell-based anti-HIV gene
therapy. Virology 411;2011: 260272.

38.

Christopher D. Pilcher, Joseph J. Eron Jr. Shannon Galvin, Cynthia Gay and
Myron S. Cohen . Acute HIV Revisited: New Opportunities For Treatment And
Prevention . The Journal of Clinical Investigation 2004.Vol 113; 7: 937-945.

39.

Lederman, M. 2004. Immunopathogenesis Of HIV Infection. (HIV InSite),

http://hivinsite.ucsf.edu/InSite?page=kb-02-01-04 (Akses: 30 Desember 2011).

40.

Althaus, C.L., De Boer, R.J. Dynamics of Immune Escape during HIV/SIV

Infection. PLoS Comput. Biol. 2008: 4 (7), e1000103.

41.

Sarwo Handayani. Deplesi Sel Limfosit CD4+ pada Infeksi HIV. Cermin Dunia
Kedokteran, 2001: No. 130; 9-11.

42.

Lane C. Immunophatogenesis of HIV Infection. Medscape HIV/AIDS. 1999.

Annual Update. Norhwestern Univ Med School.

43.

Carter, C. A. and L. S. Ehrlich. Cell biology of HIV-1 Infection Of

Macrophages. Annu Rev Microbiol 2008; 62: 425-443.

44.

Mosier, D. E. How HIV Changes Its Tropism: Evolution And Adaptation?. Curr
Opin HIV AIDS 2009; 4(2): 125-130.

45.

Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV- 1

Coreceptors: Roles In Viral Entry, Tropism, And Disease. Annu Rev Immunol
1999, 17:657700.

46.

John P. Moore, Scott G. Kitchen, Pavel Pugach, And Jerome A. Zack. The
CCR5 and CXCR4 CoreceptorsCentral to Understanding the Transmission
and Pathogenesis of Human Immunodeficiency Virus Type 1 Infection. AIDS
Research And Human Retroviruses, 2004. Vol 20 (1), Pp. 111126.

47.

Doms RW. Chemokine receptors and HIV entry. AIDS 2001;15(Suppl. 1):S34
35.

48.

Ghalib Alkhatib. The biology of CCR5 and CXCR4. Current Opinion in HIV
and AIDS 2009,4:96103.

49.

Trigg ME. Hematopoietic stem cells. Pediatrics 2004; 113:1051-7.

50.

Aschan J. Allogeneic haematopoietic stem cell transplantation: current status

and future outlook. Br Med Bull 2006; 77-78:23-36.

51.

Sierra J. Hematopoietic Transplantation. In: Imaging in transplantation. Ed:

Bankier A. Springer-Verlag Heidelberg. Berlin 2008: 177-86.

52.

Nielsen, Julie S. and Kelly M. McNagny. 2008. Novel functions of the CD34
family. J. Cell Sci. 121, 3683-3692.

53.

Doyonnas, R., Kershaw, D. B., Duhme, C., Merkens, H., Chelliah, S., Graf, T.
dan McNagny, K. M. Anuria, omphalocele, and perinatal lethality in mice
lacking the CD34-related protein podocalyxin. J. Exp. Med 2001. 194, 13-27.

54.

Reksodiputro AH. Tranplantasi sel asal/ induk darah. Dalam : Buku ajar Ilmu
Penyakit Dalam. Editor Sudoyo AW dkk. Jilid II Edisi IV. Pusat Penerbitan
Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas
Indonesia.Jakarta 2006:755-8.

55.

Milhavet, Olliver.Devin S.Gary, Mark P Mattson. RNA Interference in Biology

and Medicine. Pharmacological Review, 2003.55: 629-648.

56.

Mello CC. Return to the RNAi World: Rethinking Gene Expression And
Evolution (Nobel Lecture). Angew Chem Int Ed Engl 2007; 46:69856994.

57.

Haasnoot J, Westerhout EM, Berkhout B. RNA Interference Against Viruses:

Strike And Counterstrike. Nat Biotechnol 2007; 25:14351443.

58.

Karin J von Eije and Ben Berkhout. RNA-interference-Based Gene Therapy

Approaches to HIV Type-1 Treatment: Tackling The Hurdles From Bench To
Bedside. Antiviral Chemistry & Chemotherapy, 2009: 19:221233.

59.

Grimm D, Kay MA. Combinatorial RNAi: A Winning Strategy For The Race
Against Evolving Targets? Mol Ther 2007; 15:878888.

60.

Hannon G. RNA interference. Nature 2002;418:244-51.

61.

Ter Brake O, Konstantinova P, Ceylan M, Berkhout B. Silencing of HIV-1 with

RNA interference: a multiple shRNA approach. Mol Ther 2006; 14:883892.

62.

Ter Brake O, Berkhout B. Lentiviral vectors that carry anti- HIV shRNAs:
problems and solutions. J Gene Med 2007; 9:743750.

63.

Salmon P, Trono D. Production and titration of lentiviral vectors. Curr Protoc

Neurosci 2006; Chapter 4:Unit 4.21.

64.

Chang LJ, Liu X, He J. Lentiviral siRNAs Targeting Multiple Highly Conserved

RNA Sequences Of Human Immunodeficiency Virus Type 1. Gene Ther 2005;
12:11331144.

65.

Park F, Kay M. Modified HIV-1 Based Lentiviral Vectors Have An Effect On

Viral Transduction Efficiency And Gene Expression In Vitro And In Vivo. Mol
Ther 2001, 4:164173.

66.

Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D.

Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J
Virol 1998, 72:98739880.

67.

Ramezani A, Hawley TS, Hawley RG. Lentiviral Vectors For Enhanced Gene
Expression In Human Hematopoietic Cells. Mol Ther 2000, 2:458469.

68.

Aaron C Logan, Carolyn Lutzko and Donald B Kohn. Advances In Lentiviral

Vector Design For Gene-Modification Of Hematopoietic Stem Cells. Current
Opinion in Biotechnology 2002, 13:429436.

69.

Lin, X., J. Yang, J. Chen, A. Gunasekera, S.W. Fesik, and Y. Shen. Development
of a tightly regulated U6 promoter for shRNA expression. FEBS Lett, 2004.
577:376-380.

70.

Akkina R, Banerjea A, bai J, Anderson J, Li MJ, Rossi J. siRNAs, ribozymes,

and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS.
Anticancer Res 2003, 23:1997-2006.

71.

Frecha, C.; Szecsi, J.; Cosset, F. L. & Verhoeyen, E. Strategies for targeting
lentiviral vectors. Curr Gene Ther, 2008. Vol.8, No.6, pp. 449-460

72.

Wiznerowicz M, Trono D. Conditional Suppression Of Cellular Genes:

Lentivirus Vector-Mediated Drug-Inducible RNA Interference. J Virol 2003;
77:89578961.

73.

Kumar M, Keller B, Makalou N, Sutton RE. Systematic Determination Of The

Packaging Limit Of Lentiviral Vectors. Hum Gene Ther, 2001. 12: 18931905.

74.

Anderson, J. & Akkina, R. CXCR4 and CCR5 shRNA transgenic CD34+ Cell
Derived Macrophages Are Functionally Normal And Resist HIV-1 Infection.
Retrovirology, 2005. Vol.2, pp. 53.

75.

Kafri T, van Praag H, Gage FH, Verma IM. Lentiviral Vectors: Regulated Gene
Expression. Mol Ther 2000, 1:516521.

76.

Yam P, Li S, Wu J, Hu J, Zaia J, Yee J. Design of HIV-1 vectors for efficient

gene delivery into human hematopoietic cells. Mol Therapy 2002, 6:770-782

77.

Li M, Bauer G, Michienzi A, Yee J, Lee NS, Kim J, Li S, Castanotto D, Zaia J,

Rossi J. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol IIIpromoted anti-HIV RNAs. Mol Therapy 2003, 8:196-206.

78.

Xu K, Ma H, McCown TJ, Verma IM, Kafri T. Generation Of A Stable Cell

Line Producing High-Titer Self-Inactivating Lentiviral Vectors. Mol Ther 2001,
3:97104.

79.

Zubler RH. Ex Vivo Expansion Of Hematopoietic Stem Cells And Gene Therapy
Development. Swiss Med Wkly 2006; 136:795-9.

80.

Motonari Kondo, Amy J.Wagers,Markus G. Manz, Susan S. Prohaska,David C.

Scherer, Georg F. Beilhack, Judith A. Shizuru, And Irving L.Weissman. Biology
Of Hematopoietic Stem Cells And Progenitors: Implications For Clinical
Application .Annu. Rev. Immunol. 2003. 21:759806.

81.

Katia Pauwels Rik Gijsbers Jaan Toelen , Axel Schambach, Karen WillardGallo Cline Verheust1, Zeger Debyser and Philippe Herman. State-of-the-Art
Lentiviral Vectors for Research Risk Assessment and Biosafety
Recommendations. Current Gene Therapy, 2009, 9, 459-474.

A.

Hidalgo. Hematopoietic Stem Cell Homing: The Long, Winding And Adhesive
Road To The Bone Marow. Inmunologa 2008. Vol. 27 (1) 22-35.

82.

Adams GB, Scadden DT. The Hematopoietic Stem Cell In Its Place. Nat
Immunol 2006; 7:333-337.

83.

Abkowitz JL, Robinson AE, Kale S, Long MW, Chen J. Mobilization Of

Hematopoietic Stem Cells During Homeostasis And After Cytokine Exposure.
Blood 2003; 102:1249-1253.

84.

Wright DE, Wagers AJ, Gulati AP, Johnson FL, Weissman IL. Physiological
Migration Of Hematopoietic Stem And Progenitor Cells. Science 2001;
294:1933-1936.

85.

Zampetaki Anna, John Paul Kirton, Qingbo Xu. 2008. Vascular Repair by
Endothelial Progenitor Cells. Cardiovascular Research. 78: 413-421.

86.

Nagasawa T. The Chemokine CXCL12 And Regulation Of HSC And B

Lymphocyte Development In The Bone Marrow Niche. Adv Exp Med Biol 2007;
602:69-75

87.

Mazo IB, Gutierrez-Ramos JC, Frenette PS, Hynes RO, Wagner DD, von
Andrian UH. Hematopoietic progenitor cell rolling in bone marrow
microvessels: Parallel contributions by endothelial selectins and VCAM-1. J
Exp Med 1998; 188:465-474.

88.

Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman
ME, Et Al. Progenitor Cell Trafficking Is Regulated By Hypoxic Gradients
Through HIF-1 Induction of SDF-1. Nat Med 2004; 10:858-864.

89.

Mehta, Dolly and Asrar B. Malik. 2006. Signaling Mechanisms Regulating

Endothelial Permeability. Physiol Rev.86:279-367.

90.

Ramrez M, Segovia JC, Benet I, Arbona C, Genechea G, Blaya C,. Ex Vivo

Expansion Of Umbilical Cord Blood (UCB) CD34+ Cells Alters The
Expression And Function Of 41and 51-Integrins. Br J Haematol 2001;
115:213-221.

91.

Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M,

Rovner A, Ellis SG, Thomas JD, DiCorleto PE, Topol EJ, Penn MS. 2003.
Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue
regeneration in ischaemic cardiomyopathy. Lancet. 362: 697703.

92.

Winkler IG, Levesque JP. Mechanisms Of Hematopoietic Stem Cell

Mobilization: When Innate Immunity Assails The Cells That Make Blood And
Bone. Exp Hematol 2006; 34:996-1009.

93.

Ceradini DJ, Gurtner GC. Homing To Hypoxia: HIF-1 As A Mediator Of

Progenitor Cell Recruitment To Injured Tissue. Trends Cardiovasc Med 2005;
15:57-63.

94.

Schmidt, Annette ., Klara Brixius and Wilhelm Bl. 2007. Endothelial Precursor
Cell Migration During Vasculogenesis. Circ. Res.101;125-136.

95.

Gustavo Tiscornia, Oded Singer, and Inder M. Verma. Development of

Lentiviral Vectors Expressing siRNA. Copyright 2007 Cold Spring Harbor
Laboratory Press.

96.

Amarzguioui, M., Rossi, J.J., and Kim, D. Approaches form chemically

synthesized siRNA and vector-mediated RNAi. FEBS Lett. 2005. 579: 5974
5981.

97.

Cullen, B. R. 2002. RNA interference: antiviral defense and genetic tool. Nat.
Immunol. 3:5979.

98.

Elbashir, S. M., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl.

2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured
mammalian cells. Nature 411:49498.

99.

Tomari Y, Zamore PD. Perspective: machines for RNAi. Gen Dev 2005; 19:
517-29.

100. Stevenson M. Therapeutic Potential of RNA Interference. N Engl J Med 2004;

351(17): 1772-7.
101. Murray, J. M., G. C. Fanning. Mathematical Modelling Of The Impact Of
Haematopoietic Stem Cell-Delivered Gene Therapy For HIV.J Gene Med, 2009.
11(12): 1077-1086.
102. Holt, N., Wang, J., Kim, K., Friedman, G., Wang, X., Taupin, V., Crooks, G.M.,
Kohn, D.B., Gregory, P.D., Holmes, M.C., Cannon, P.M.. Human
Hematopoietic Stem/ Progenitor Cells Modified By Zinc-Finger Nucleases

Targeted To CCR5 Control HIV-1 In Vivo. Nat. Biotechnol, 2009. 28 (8), 839
847.
103. Liang, M., Kamata, M., Chen, K.N., Pariente, N., An, D.S., Chen, I.S.
Inhibition Of HIV-1 Infection By A Unique Short Hairpin RNA To Chemokine
Receptor 5 Delivered Into Macrophages Through Hematopoietic Progenitor
Cell Transduction. J. Gene Med, 2010. 12 (3), 255265
104. Joseph, A., Zheng, J.H., Chen, K., Dutta, M., Chen, C., Stiegler, G., Kunert, R.,
Follenzi, A., Goldstein, H. Inhibition Of In Vivo HIV Infection In Humanized
Mice By Geneherapy Of Human Hematopoietic Stem Cells With A Lentiviral
Vector Encoding A Broadly Neutralizing Anti-HIV Antibody. J. Virol, 2010. 84
(13), 66456653.
105. Luo, X.M., Maarschalk, E., O'Connell, R.M., Wang, P., Yang, L., Baltimore, D.
Engineering Human Hematopoietic Stem/Progenitor Cells To Produce A
Broadly Neutralizing Anti-HIV Antibody After In Vitro Maturation To Human B
Lymphocytes. Blood, 2009. 113 (7), 14221431.
106. Kambal, A., Mitchell, G., Cary, W., Gruenloh, W., Jung, Y., Kalomoiris, S.,
Nacey, C., McGee, J., Lindsey, M., Fury, B., Bauer, G., Nolta, J.A., Anderson,
J.S . Generation Of HIV-1 Resistant And Functional Macrophages From
Hematopoietic Stem Cellderived Induced Pluripotent Stem Cells. Mol. Ther,
2010. doi:10.1038/mt.2010.269.
107. Moretta L, Ferlazzo G, Bottino C,. Effector And Regulatory Events During
Natural Killer Dendritic Cell Interactions. Immunol Rev. 2006; 214:219-228.
108. Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA. NK cell and DC
interactions. Trends Immunol. 2004;25:47-52.
109. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, Coactivation,
And Costimulation Of Resting Human Natural Killer Cells. Immunol Rev.
2006;214:73-91.
110. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural Killer Cell
Receptors: New Biology And Insights Into The Graft-Versusleukemia Effect.
Blood. 2002;100:1935-1947.
111. Ruggeri L, Aversa F, Martelli MF, Velardi A. Allogeneic Hematopoietic
Transplantation And Natural Killer Cell Recognition Of Missing Self. Immunol
Rev. 2006;214:202-218.
112. Anonim. Small Hairpin RNA [shRNA]. www.wikipedia.com (Akses 1 Januari
2012)